Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical benefit of early treatment with bone-modifying agents for preventing skeletal-related events in patients with genitourinary cancer with bone metastasis: A multi-institutional retrospective study.
Owari T, Miyake M, Nakai Y, Hori S, Tomizawa M, Ichikawa K, Shimizu T, Iida K, Samma S, Iemura Y, Momose H, Omori C, Otani T, Kuwada M, Hirao S, Oyama N, Nakagawa Y, Hayashi Y, Tanaka N, Fujimoto K. Owari T, et al. Among authors: omori c. Int J Urol. 2019 Jun;26(6):630-637. doi: 10.1111/iju.13939. Epub 2019 Mar 18. Int J Urol. 2019. PMID: 30883931
Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab.
Shimizu T, Miyake M, Hori S, Ichikawa K, Omori C, Iemura Y, Owari T, Itami Y, Nakai Y, Anai S, Tomioka A, Tanaka N, Fujimoto K. Shimizu T, et al. Among authors: omori c. Diagnostics (Basel). 2020 May 15;10(5):310. doi: 10.3390/diagnostics10050310. Diagnostics (Basel). 2020. PMID: 32429323 Free PMC article.
Impact of Complete Surgical Resection of Metastatic Lesions in Patients with Advanced Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors.
Shimizu T, Miyake M, Nishimura N, Yoshida T, Itami Y, Tachibana A, Omori C, Oda Y, Kohashi M, Tomizawa M, Onishi K, Hori S, Morizawa Y, Dotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K. Shimizu T, et al. Among authors: omori c. Cancers (Basel). 2024 Feb 19;16(4):841. doi: 10.3390/cancers16040841. Cancers (Basel). 2024. PMID: 38398232 Free PMC article.
Clinical significance of limited and extended pelvic lymph node dissection during robot-assisted radical prostatectomy for patients with localized prostate cancer: A retrospective, propensity score matching analysis.
Hori S, Nakai Y, Tachibana A, Omori C, Nishimura N, Inoue K, Tomizawa M, Shimizu T, Morizawa Y, Gotoh D, Miyake M, Torimoto K, Yoneda T, Fujimoto K, Tanaka N. Hori S, et al. Among authors: omori c. Int J Urol. 2023 Feb;30(2):168-175. doi: 10.1111/iju.15075. Epub 2022 Oct 28. Int J Urol. 2023. PMID: 36305671
First-line pembrolizumab for patients with early relapsing urothelial carcinoma after perioperative chemotherapy: a retrospective analysis of bladder cancer and upper urinary tract cancer.
Nishimura N, Miyake M, Shimizu T, Matsubara T, Miyamoto T, Sakamoto K, Yamada A, Matsumoto Y, Yoshikawa M, Ichikawa K, Omori C, Maesaka F, Oda Y, Kiba K, Tomioka A, Hosokawa Y, Tanaka M, Otani T, Fujimoto K. Nishimura N, et al. Among authors: omori c. Int J Clin Oncol. 2022 Nov;27(11):1733-1741. doi: 10.1007/s10147-022-02230-9. Epub 2022 Aug 27. Int J Clin Oncol. 2022. PMID: 36029377
Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study.
Shimizu T, Miyake M, Nishimura N, Inoue K, Fujii K, Iemura Y, Ichikawa K, Omori C, Tomizawa M, Maesaka F, Oda Y, Miyamoto T, Sakamoto K, Kiba K, Tanaka M, Oyama N, Okajima E, Fujimoto K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K. Shimizu T, et al. Among authors: omori c. Cancers (Basel). 2022 Mar 29;14(7):1735. doi: 10.3390/cancers14071735. Cancers (Basel). 2022. PMID: 35406508 Free PMC article.
51 results